|
US10519504B2
(en)
|
2009-05-11 |
2019-12-31 |
Berg Llc |
Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
|
|
EP2982978A1
(en)
|
2009-05-27 |
2016-02-10 |
Immunaid Pty Ltd |
Methods of treating diseases
|
|
EP3151012B1
(en)
*
|
2010-09-21 |
2018-03-21 |
Proteomics International Pty Ltd |
Biomarkers associated with diabetic nephropathy
|
|
US9220776B2
(en)
*
|
2011-03-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
|
|
EP2694463B8
(en)
|
2011-04-04 |
2019-10-09 |
Berg LLC |
Treating central nervous system tumors with coenzyme q10
|
|
DK2634195T3
(en)
*
|
2012-03-01 |
2017-02-27 |
Miltenyi Biotec Gmbh |
Separation of living pristine neurons
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
WO2013192191A1
(en)
*
|
2012-06-18 |
2013-12-27 |
Mayo Foundation For Medical Education And Research |
Determination of efficient time(s) for chemotherapy delivery
|
|
EA032775B1
(ru)
|
2013-04-08 |
2019-07-31 |
Берг Ллк |
Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
|
|
HRP20210122T1
(hr)
|
2013-05-02 |
2021-04-16 |
Anaptysbio, Inc. |
Protutijela usmjerena protiv programirane smrti-1 (pd-1)
|
|
WO2015035094A1
(en)
|
2013-09-04 |
2015-03-12 |
Berg Llc |
Methods of treatment of cancer by continuous infusion of coenzyme q10
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3114144A1
(en)
*
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
MX391478B
(es)
|
2014-10-10 |
2025-03-21 |
Idera Pharmaceuticals Inc |
Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
|
|
EP3943101A1
(en)
|
2014-10-21 |
2022-01-26 |
SciClone Pharmaceuticals International Ltd. |
Treatment of cancer with immune stimulator alpha thymosin peptide
|
|
US9765147B2
(en)
|
2014-10-29 |
2017-09-19 |
Five Prime Therapeutics, Inc. |
Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
|
|
JP2016148623A
(ja)
*
|
2015-02-13 |
2016-08-18 |
京都府公立大学法人 |
大腸がんの検出方法
|
|
LT3283527T
(lt)
|
2015-04-13 |
2021-03-25 |
Five Prime Therapeutics, Inc. |
Kompleksinė terapija vėžio gydymui
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
US10996217B2
(en)
*
|
2015-08-06 |
2021-05-04 |
Sekisui Medical Co., Ltd. |
Method for examining renal disease
|
|
FI3334763T3
(fi)
*
|
2015-08-11 |
2024-10-30 |
Wuxi Biologics Ireland Ltd |
Uusia pd-l1-vasta-aineita
|
|
WO2017087576A1
(en)
|
2015-11-16 |
2017-05-26 |
Berg Llc |
Methods of treatment of temozolomide-resistant glioma using coenzyme q10
|
|
TW202208440A
(zh)
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
CA3016474A1
(en)
|
2016-03-15 |
2017-09-21 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
US20180021270A1
(en)
*
|
2016-07-21 |
2018-01-25 |
Berg Llc |
Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
|
|
US20190269666A1
(en)
*
|
2016-07-29 |
2019-09-05 |
Eli Lilly And Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
|
EP3666794A1
(en)
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
CN110382545A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗pd-1抗体治疗癌症的方法
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
EP3619230A4
(en)
*
|
2017-05-01 |
2021-04-21 |
The Children's Medical Center Corporation |
PROCEDURES AND COMPOSITIONS RELATED TO ANTI-PD1 ANTIBODY REAGENTS
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
SG11201909955XA
(en)
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
US12070489B2
(en)
|
2018-12-12 |
2024-08-27 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with a cancer therapy in combination with another therapeutic agent
|
|
EP3635410A4
(en)
*
|
2017-06-04 |
2021-03-10 |
Rappaport Family Institute for Research in the Medical Sciences |
PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
|
|
US12016900B2
(en)
|
2017-06-04 |
2024-06-25 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
|
|
MX2020002301A
(es)
|
2017-09-13 |
2020-07-13 |
Five Prime Therapeutics Inc |
Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
|
|
US11946937B2
(en)
*
|
2017-09-13 |
2024-04-02 |
Mayo Foundation For Medical Education And Research |
Identification and monitoring of apoptosis inhibitor of macrophage
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
EP3924521A4
(en)
|
2019-02-15 |
2023-03-29 |
IncellDx, Inc. |
Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
|
|
JP2022531444A
(ja)
|
2019-05-06 |
2022-07-06 |
ブラウン ユニバーシティ |
腫瘍細胞に対するｔ細胞を介した細胞傷害効果が増大したｃｈｉ３ｌ１およびｐｄ１に対する二重特異性抗体
|
|
US11890285B2
(en)
|
2019-09-24 |
2024-02-06 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US11908560B2
(en)
|
2021-08-11 |
2024-02-20 |
OncoHost Ltd. |
Cancer process evaluation
|
|
CN119343370A
(zh)
*
|
2022-06-08 |
2025-01-21 |
浙江时迈药业有限公司 |
针对enpp3的抗体及其用途
|
|
EP4650781A1
(en)
*
|
2023-01-10 |
2025-11-19 |
Toru Miyazaki |
Method for diagnosing cancer
|
|
WO2025034883A1
(en)
|
2023-08-08 |
2025-02-13 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|
|
WO2025106905A1
(en)
|
2023-11-17 |
2025-05-22 |
Quanta Therapeutics, Inc. |
Combination therapies with a kras modulator and an immunomodulator inhibitor
|